Sana Biotechnology has big plans after securing $700M initial financing

Sana Biotechnology, a Seattle-based company developing cell and gene therapies, announced it has raised more than $700 million to aid in the discovery and development of gene modifications.

Photo: Sana President and CEO Steve Harr, MD (courtesy Sana Biotechnology)

READ THE STORY at Puget Sound Business Journal »